Peter Atadja

Peter Atadja

UNVERIFIED PROFILE

Are you Peter Atadja?   Register this Author

Register author
Peter Atadja

Peter Atadja

Publications by authors named "Peter Atadja"

Are you Peter Atadja?   Register this Author

100Publications

2719Reads

9Profile Views

HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2 Tumors.

Cancer Res 2017 05 1;77(10):2594-2606. Epub 2017 Mar 1.

Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Victorian Comprehensive Cancer Centre (VCCC), Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-16-2247DOI Listing
May 2017

Current trends in outwitting resistance development in Candida infections through photodynamic and short peptide therapies: a strategic-shift from conventional antifungal agents.

Expert Rev Anti Infect Ther 2016 ;14(3):345-52

a School of Basic and Biomedical Sciences (SBBS) , The University of Health and Allied Sciences , Ho , Volta Region , Ghana.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1586/14787210.2016.11
Publisher Site
http://dx.doi.org/10.1586/14787210.2016.1147953DOI Listing
October 2016

Histone Demethylase LSD1 Promotes Adipocyte Differentiation through Repressing Wnt Signaling.

Cell Chem Biol 2016 Oct 15;23(10):1228-1240. Epub 2016 Sep 15.

China Novartis Institutes for BioMedical Research, 4218 Jinke Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai 201203, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2016.08.010DOI Listing
October 2016

Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.

Clin Epigenetics 2015 22;7. Epub 2015 Jan 22.

Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, 3002 VIC Australia ; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, 3010 VIC Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13148-014-0034-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308003PMC
January 2015

Absolute quantification of histone PTM marks by MRM-based LC-MS/MS.

Anal Chem 2014 Oct 8;86(19):9679-86. Epub 2014 Sep 8.

China Novartis Institutes for BioMedical Research Co. Ltd. , Building 8, Lane 898 Halei Road, Shanghai 201203, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ac502333aDOI Listing
October 2014

Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.

Mol Cell 2014 Jan 2;53(2):247-61. Epub 2014 Jan 2.

Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Biological Chemistry, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molcel.2013.12.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965208PMC
January 2014

NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.

Cancer Res 2013 Oct 26;73(20):6277-88. Epub 2013 Aug 26.

Authors' Affiliations: Novartis Institutes for BioMedical Research (China), Shanghai, P.R. China; Genomics Institute of the Novartis Research Foundation, San Diego, California; and Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1000DOI Listing
October 2013

ING1 and 5-azacytidine act synergistically to block breast cancer cell growth.

PLoS One 2012 20;7(8):e43671. Epub 2012 Aug 20.

Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0043671PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423394PMC
January 2013

Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589).

Drug Metab Dispos 2012 May 16;40(5):1041-50. Epub 2012 Feb 16.

Global Ciscovery Chemistry, Novartis Institutes for BioMedical Research, WKL-122.P.37, CH-4002 Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/dmd.111.043620DOI Listing
May 2012

Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation.

J Biol Chem 2011 Nov 31;286(44):38725-37. Epub 2011 Aug 31.

Novartis Institutes for BioMedical Research, Building 8, Lane 898, Halei Road, Pudong, Shanghai 201203, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M111.262410DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207477PMC
November 2011

Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat.

Int J Cancer 2011 Jun 13;128(11):2735-47. Epub 2010 Oct 13.

Cancer Therapeutics Program, The Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.25594DOI Listing
June 2011

HDAC inhibitors and cancer therapy.

Authors:
Peter W Atadja

Prog Drug Res 2011 ;67:175-95

Novartis Institute for Biomedical Research, 898 Halei Rd, Building 8, Shanghai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-7643-8989-5_9DOI Listing
January 2011

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.

Authors:
Peter Atadja

Cancer Lett 2009 Aug 2;280(2):233-41. Epub 2009 Apr 2.

Novartis Institutes for Biomedical Research, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2009.02.019DOI Listing
August 2009

Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6.

Radiother Oncol 2009 Jul 28;92(1):125-32. Epub 2009 Mar 28.

Department of Radiation Oncology, Seoul National University School of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2009.03.008DOI Listing
July 2009

High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model.

Clin Cancer Res 2009 Jun 9;15(12):4066-76. Epub 2009 Jun 9.

Department of General Medical Oncology, Laboratory of Experimental Oncology, University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-08-2588DOI Listing
June 2009

Epigenetics in cancer: targeting chromatin modifications.

Mol Cancer Ther 2009 Jun 9;8(6):1409-20. Epub 2009 Jun 9.

Peter MacCallum Cancer Center, St. Andrews Place, East Melbourne 3002, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0860DOI Listing
June 2009

Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.

Mol Cancer Ther 2008 Oct;7(10):3285-97

Department of Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia 23298, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2586957PMC
October 2008

HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.

Blood 2008 Sep 30;112(5):1886-93. Epub 2008 Jun 30.

Medical College of Georgia (MCG) Cancer Center, Augusta, GA 30912, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2008-03-143644DOI Listing
September 2008

Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.

Neuro Oncol 2008 Jun 29;10(3):309-19. Epub 2008 Apr 29.

Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1215/15228517-2007-063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2563053PMC
June 2008

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.

Clin Cancer Res 2008 Jun;14(11):3589-97

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Cancer Research Building I, 1M52, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-4306DOI Listing
June 2008

Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells.

Mol Cancer Res 2008 May;6(5):873-83

The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB Room 144, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1541-7786.MCR-07-0330DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361136PMC
May 2008

Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.

Mol Cancer Ther 2007 Sep;6(9):2515-24

Thoracic Oncology and Experimental Therapeutics Programs, H. Lee Moffitt Cancer Center and Research Institute, MRC3 East, Room 3056, 12902 Magnolia Drive, Tampa, FL 33612-9497, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-06-0761DOI Listing
September 2007

Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation.

Cancer Biol Ther 2007 Jan;6(1):64-9

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB Room 409, Baltimore, Maryland 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.6.1.3549DOI Listing
January 2007

Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.

Mol Cancer Ther 2007 Jan;6(1):70-81

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins School of Medicine, Bunting-Blaustein Cancer Research Building 1M52, 1650 Orleans Street, Baltimore, Maryland, MD 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-06-0125DOI Listing
January 2007

Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.

Cancer Res 2006 Dec;66(23):11298-304

Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-06-0049DOI Listing
December 2006

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.

Mol Cancer Ther 2006 Dec;5(12):3096-104

Medical College of Georgia Cancer Center, 1120 15th Street, CN2101A, Augusta, GA 30912, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-06-0418DOI Listing
December 2006

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.

Cancer Res 2006 Sep;66(17):8814-21

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-54
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-05-4598DOI Listing
September 2006

In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.

Cancer Res 2006 Aug;66(15):7621-9

Molecular Therapy and Cancer Cell Biology, Imperial College London, Faculty of Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-05-3962DOI Listing
August 2006

The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.

Cancer Res 2006 Jun;66(11):5781-9

Centro de Investigación del Cáncer, Consejo Superior de Investigaciones Cientificas, Universidad de Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-05-4186DOI Listing
June 2006

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

Clin Cancer Res 2006 Jan;12(2):634-42

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building 1M52, 1650 Orleans Street, Baltimore, MS 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-1132DOI Listing
January 2006

Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.

Mol Cancer Ther 2005 Nov;4(11):1772-85

Department of Medicine, Virginia Commonwealth University/Medical College of Virginia, MCV Station Box 230, Richmond, VA 23298, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-05-0157DOI Listing
November 2005

Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.

Mol Cancer Ther 2005 Sep;4(9):1311-9

Molecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-04-0287DOI Listing
September 2005

Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824.

Novartis Found Symp 2004 ;259:249-66; discussion 266-8, 285-8

Department of Oncology Molecular and Cellular Biology, Novartis Institutes for Biomedical Research, East Hanover, NJ 07936, USA.

View Article

Download full-text PDF

Source
June 2004

Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.

Haematologica 2004 Apr;89(4):419-26

Med. Klinik III/Abtl. Hämatologie, Johann Wolfgang Goethe-Universität, 60590 Frankfurt, Germany.

View Article

Download full-text PDF

Source
April 2004